文献速递糖尿病

SGLT2抑制剂联合胰高血糖素受体拮抗剂治疗1型糖尿病:一项随机临床试验

Combination SGLT2 Inhibitor and Glucagon Receptor Antagonist Therapy in Type 1 Diabetes: A Randomized Clinical Trial.
PubMed 文献 · Diabetes Care · 2025-01-01

这项随机双盲安慰剂对照交叉试验在12名1型糖尿病成人中评估达格列净10mg每日联合volagidemab 70mg每周的辅助治疗。联合治疗较基线及单用SGLT2抑制剂改善平均血糖和血糖在范围内时间,减少每日胰岛素用量,并降低胰岛素缺乏期间β-羟基丁酸峰值。联合治疗未增加低血糖,参与者报告治疗可接受度和满意度提高。

要点

  • 联合治疗较基线及单用SGLT2抑制剂改善血糖控制并减少胰岛素用量。
  • 联合治疗期间胰岛素缺乏试验中β-羟基丁酸峰值低于单用SGLT2抑制剂,与基线相似。
  • 联合治疗未增加低血糖,参与者报告治疗可接受度和满意度提高。

核心结论

  • 胰高血糖素拮抗增强了SGLT2抑制在1型糖尿病中的治疗效应。
  • 联合治疗改善血糖控制、减少胰岛素用量,并提示一种策略:释放SGLT2抑制剂的获益同时减轻糖尿病酮症酸中毒风险。

研究设计与样本

  • 随机、双盲、安慰剂对照交叉试验,纳入12名1型糖尿病成人。
  • 评估达格列净10 mg每日单用及联合volagidemab 70 mg每周的辅助治疗。
  • 在仅胰岛素(基线)、SGLT2抑制剂及联合治疗期间完成连续血糖监测、胰岛素剂量及胰岛素撤退试验。

主要发现

  • 平均血糖:联合治疗131 mg/dL vs 基线150 mg/dL(P < 0.001)vs SGLT2抑制剂138 mg/dL(P = 0.01)。
  • 血糖在范围内(70-180 mg/dL)时间百分比:联合治疗86% vs 基线70%(P < 0.001)vs SGLT2抑制剂78%(P = 0.03)。
  • 每日总胰岛素用量:联合治疗0.41 vs 基线0.56 units/kg/day(P < 0.001)vs SGLT2抑制剂0.52 units/kg/day(P = 0.002)。
  • 胰岛素撤退试验中β-羟基丁酸峰值:联合治疗2.0 mmol/L vs SGLT2抑制剂2.4 mmol/L(P = 0.048),与基线2.1 mmol/L相似。
  • 联合治疗未增加低血糖,参与者报告治疗可接受度和满意度提高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the effects of insulin-adjunctive therapy with a sodium-glucose cotransporter 2 (SGLT2) inhibitor and a glucagon receptor antagonist (GRA) on glycemia, insulin use, and ketogenesis during insulinopenia in type 1 diabetes. RESEARCH DESIGN AND METHODS: In a randomized, double-blind, placebo-controlled, crossover trial we assessed the effects of adjunctive SGLT2 inhibitor therapy (dapagliflozin 10 mg daily) alone and in combination with the GRA volagidemab (70 mg weekly) in 12 adults with type 1 diabetes. Continuous glucose monitoring, insulin dosing, and insulin withdrawal tests (IWT) for measurement of glucose and ketogenesis during insulinopenia were completed during insulin-only (Baseline), SGLT2 inhibitor, and combination (SGLT2 inhibitor + GRA) therapy periods. RESULTS: Average glucose and percent time with glucose in range (70-180 mg/dL) improved with combination therapy versus Baseline and SGLT2 inhibitor (131 vs. 150 and 138 mg/dL [P < 0.001 and P = 0.01] and 86% vs. 70% and 78% [P < 0.001 and P = 0.03], respectively) without increased hypoglycemia. Total daily insulin use decreased with combination therapy versus Baseline and SGLT2 inhibitor (0.41 vs. 0.56 and 0.52 units/kg/day [P < 0.001 and P = 0.002]). Peak β-hydroxybutyrate levels during IWT were lower with combination therapy than with SGLT2 inhibitor (2.0 vs. 2.4 mmol/L; P = 0.048) and similar to levels reached during the Baseline testing period (2.1 mmol/L). Participants reported enhanced treatment acceptability and satisfaction with combination therapy. CONCLUSIONS: Glucagon antagonism enhances the therapeutic effects of SGLT2 inhibition in type 1 diabetes. Combination therapy improves glycemic control, reduces insulin dosing, and suggests a strategy to unlock the benefits of SGLT2 inhibitors while mitigating the risk of diabetic ketoacidosis.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Boeder SC, Thomas RL, Le Roux MJ, et al. Combination SGLT2 Inhibitor and Glucagon Receptor Antagonist Therapy in Type 1 Diabetes: A Randomized Clinical Trial. Diabetes Care. 2025. PMID: 38776437. doi:10.2337/dc24-0212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。